Gastro-Resistant Omeprazole Capsules

Therapeutic Class: Gastrointestinals

Dosage Forms: Hard Capsules

Brand Name: Omeconex-20

Packaging Available In Alu/PVC Blister

Pack Size: 30x10 Softgels

Omeprazole Capsules Manufacturers, Suppliers, and Exporters in India.

How it works?

Uses of Gastro-Resistant Omeprazole Capsules

Gastro-resistant Omeprazole Capsules BP 20 mg use for Treatment of duodenal ulcers

Prevention of relapse of duodenal ulcers

Treatment of gastric ulcers

Prevention of relapse of gastric ulcers

In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic ulcer disease

Treatment of NSAID-associated gastric and duodenal ulcers

Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk

Treatment of reflux oesophagitis

Long-term management of patients with healed reflux oesophagitis

Treatment of symptomatic gastro-oesophageal reflux disease

Treatment of Zollinger-Ellison syndrome

Paediatric use

Children over 1 year of age and ≥10 kg:

Treatment of reflux esophagitis

Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease

Children and adolescents over 4 years of age:

In combination with antibiotics in treatment of duodenal ulcer caused by H. pylori

Dosages administration of Gastro-Resistant Omeprazole Capsules

The recommended dose in patients with an active duodenal ulcer is Omeprazole 20mg once daily.

Side effects of Gastro-Resistant Omeprazole Capsules

Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, Fundic gland polyps (benign), Headache.

Precautions of Gastro-Resistant Omeprazole Capsules

In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis.

Omeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.

Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with omeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered.
Some children with chronic illnesses may require long-term treatment although it is not recommended.

Hypomagnesaemia: Severe hypomagnesaemia has been reported in patients treated with PPIs like omeprazole for at least three months, and in most cases for a year. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.

Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.

Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter.

As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.

Proton pump inhibitors are associated with very infrequent cases of Subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Omeprazole Capsules.

Storage instruction of Gastro-Resistant Omeprazole Capsules

  • Store below 30°C temperature. Protect from light and moisture.
  • Keep the medicine out of reach of children.

Packing details of Gastro-Resistant Omeprazole Capsules

Alu-Alu blister packs.
Omeconex-20 is available in an Alu-Alu blister of 10 capsules. Such 10 blister with package insert in a carton.

F. A. Q

Frequently Asked Questions

Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.

A pharma CMO is a special kind of an organization, offering contract manufacturing services to pharmaceutical companies for various kinds of drug formulations.

Reduce overall costs and time to market :
Contract manufacturers already have the needed infrastructure and technical staff, so working with a CMO or CDMO can decrease the cost of manufacturing your pharmaceutical products.

Scalability and flexible production capacity :
You can produce what you need when you need it without worrying about excess capacity. Additionally, CMOs understand the importance of quality and compliance, so you don't have to sacrifice safety for scalability.

Save on upgrading and maintaining equipment :
If you have your manufacturing facility, you’ll have to pay to upgrade your equipment as technology advances—which can get expensive. A CMO/CDMO’s only function is to make and distribute products, so part of their core business responsibility is to update their equipment whenever needed and perform maintenance.

Ease supply chain issues :
During the pandemic, there were several instances of supply chain issues, including medicine shortages. CMOs are generally better equipped than startups to handle a supply chain crisis.

Bandwidth to focus on core competencies
When your company resources aren’t directly allocated to manufacturing and distribution, you have more time to focus on other tasks, like marketing your new drug, researching, or working on drug discovery.

We have 7+ manufacturing sites with a minimum of WHO GMP certification and other country-specific approvals like NAFDAC approved, PPK Kenya Approved, TFDA Tanzania Approved, EU-GMP Approved.

We have below manufacturing capacity:
For Tablet, Capsule, and soft gel: up to 1 million units per shift
For Syrup: up to 0.05 Million per shift
For Ampoule and Vial: up to 0.1 million units per shift
For Ointment and Cream: up to 0.1 million units per shift
For Suppository: 0.1 Million units per shift

interested? let’s talk.

Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.

Please enable JavaScript in your browser to complete this form.

Get Your Business Quote in 24 Hour

Fill out the form below, and we will be in touch shortly.
Please enable JavaScript in your browser to complete this form.
IPHEX 2025 New Delhi CPHI Frankfurt MESSE FRANKFURT